PRECIGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
PRECIGEN, INC. (PGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 183.89 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-04
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 66.40K shares, a 1120.96% increase year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 117.49K shares, a 60.60% decline year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 2.97K shares, a 99.47% decline year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 27.50K shares, a 93.38% decline year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 334.08K shares, a 78.95% decline from fiscal 2024.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.59M shares, a 476.47% increase from fiscal 2023.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 275.25K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 66.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 183.89K shares 10-Q · filed 2026-08-04 | 186.86K shares derived: sum of 3 quarters · filed 2026-08-04 | 214.36K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 117.49K shares 10-Q · filed 2026-05-13 | 120.46K shares derived: sum of 2 quarters · filed 2026-05-13 | 147.96K shares derived: sum of 3 quarters · filed 2026-05-13 | 153.40K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 2.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 30.47K shares derived: sum of 2 quarters · filed 2026-03-25 | 35.91K shares derived: sum of 3 quarters · filed 2026-03-25 | 334.08K shares 10-K · filed 2026-03-25 |
| 2025-09-30 | 27.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 32.94K shares derived: sum of 2 quarters · filed 2025-11-13 | 331.11K shares 10-Q · filed 2025-11-13 | 890.38K shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | 5.44K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 303.61K shares 10-Q · filed 2025-08-12 | 862.88K shares derived: sum of 3 quarters · filed 2026-03-25 | 1.28M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | 298.17K shares 10-Q · filed 2025-05-14 | 857.44K shares derived: sum of 2 quarters · filed 2026-03-25 | 1.27M shares derived: sum of 3 quarters · filed 2026-03-25 | 1.64M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | 559.27K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 974.98K shares derived: sum of 2 quarters · filed 2026-03-25 | 1.35M shares derived: sum of 3 quarters · filed 2026-03-25 | 1.59M shares 10-K · filed 2026-03-25 |
| 2024-09-30 | 415.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 787.46K shares derived: sum of 2 quarters · filed 2024-11-14 | 1.03M shares 10-Q · filed 2024-11-14 | 1.06M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-06-30 | 371.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 611.75K shares 10-Q · filed 2024-08-14 | 643.00K shares derived: sum of 3 quarters · filed 2026-03-25 | 666.38K shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-03-31 | 240.00K shares 10-Q · filed 2024-05-14 | 271.25K shares derived: sum of 2 quarters · filed 2026-03-25 | 294.63K shares derived: sum of 3 quarters · filed 2026-03-25 | |
| 2023-12-31 | 31.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 54.63K shares derived: sum of 2 quarters · filed 2026-03-25 | 275.25K shares 10-K · filed 2026-03-25 | |
| 2023-09-30 | 23.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 244.00K shares 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | 220.63K shares 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |